Curated News
By: NewsRamp Editorial Staff
May 27, 2026

TransCode Therapeutics Initiates Phase 2a Trial for TTX-MC138 in Colorectal Cancer

Discuss on Substack
Original Source

TLDR

  • TransCode Therapeutics' Phase 2a trial for TTX-MC138 targets high-risk colorectal cancer patients, potentially reducing recurrence and offering a competitive edge.
  • TTX-MC138 targets microRNA-10b in metastatic tumors, tested via Quantum Leap's PRE-I-SPY platform in 45 ctDNA-positive colorectal cancer patients.
  • This trial aims to reduce cancer recurrence risk, improving survival and quality of life for patients with minimal residual disease.
  • TransCode's TTX-MC138 targets microRNA-10b, a unique biomarker of metastasis, in a novel approach to prevent cancer recurrence.

Impact - Why it Matters

This news matters because it addresses a critical unmet need in oncology: patients with minimal residual disease (ctDNA-positive but no radiographic evidence) are at high risk of recurrence and have few options. If successful, TTX-MC138 could become a first-in-class therapy to prevent metastasis, potentially changing treatment paradigms for colorectal and other cancers. The use of the PRE-I-SPY platform also highlights a shift toward more efficient clinical trial designs that could bring life-saving drugs to patients faster.

Summary

TransCode Therapeutics (NASDAQ: RNAZ) has taken a significant step forward in the fight against cancer by initiating a Phase 2a clinical trial for its lead therapeutic candidate, TTX-MC138. The trial will enroll up to 45 colorectal cancer patients who have completed curative-intent therapy but remain positive for circulating tumor DNA (ctDNA), a marker of minimal residual disease, despite no signs of cancer on imaging. This high-risk population faces a substantial chance of recurrence, and TTX-MC138 aims to reduce that risk by targeting microRNA-10b, a biomarker linked to metastasis. The study is being conducted in collaboration with Quantum Leap Healthcare Collaborative through its innovative PRE-I-SPY clinical trial platform, which is designed to accelerate the evaluation of promising therapies.

TTX-MC138 is a first-in-class RNA therapeutic that targets metastatic tumors overexpressing microRNA-10b, a key driver of cancer spread. TransCode Therapeutics is a clinical stage company focused on immuno-oncology and RNA-based treatments for advanced cancers. Beyond TTX-MC138, the company has a pipeline of other candidates designed to mobilize the immune system against cancer cells. The initiation of this trial marks a critical milestone for TransCode and offers hope for patients with minimal residual disease, a condition often overlooked in clinical trials.

For investors and the broader biotech community, the progress of TransCode is closely watched. The latest news and updates relating to RNAZ are available in the company’s newsroom. This announcement was disseminated by BioMedWire, a specialized communications platform focused on the biotechnology and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides a range of services including press release distribution, editorial syndication to 5,000+ outlets, and social media distribution. The collaboration between TransCode and Quantum Leap underscores the growing trend of using adaptive trial platforms to fast-track cancer treatments.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Therapeutics Initiates Phase 2a Trial for TTX-MC138 in Colorectal Cancer

blockchain registration record for this content.